{ "meta": { "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.", "terms": "https://open.fda.gov/terms/", "license": "https://open.fda.gov/license/", "last_updated": "2026-07-30", "results": { "skip": 0, "limit": 1, "total": 1 } }, "results": [ { "safetyreportversion": "2", "safetyreportid": "21210441", "primarysourcecountry": "CA", "occurcountry": "CA", "transmissiondateformat": "102", "transmissiondate": "20230722", "reporttype": "1", "serious": "1", "seriousnessdeath": "2", "seriousnesslifethreatening": "2", "seriousnesshospitalization": "2", "seriousnessdisabling": "2", "seriousnesscongenitalanomali": "2", "seriousnessother": "1", "receivedateformat": "102", "receivedate": "20220815", "receiptdateformat": "102", "receiptdate": "20230623", "fulfillexpeditecriteria": "1", "companynumb": "CA-BIOGEN-2022BI01147332", "duplicate": "1", "reportduplicate": [ { "duplicatesource": "E2B_Duplicate", "duplicatenumb": "E2B_03495017" }, { "duplicatesource": "E2B_Duplicate", "duplicatenumb": "2676936" } ], "primarysource": { "reportercountry": "CA", "qualification": "1" }, "sender": { "sendertype": "2", "senderorganization": "FDA-Public Use" }, "receiver": { "receivertype": "6", "receiverorganization": "FDA" }, "patient": { "patientonsetage": "48", "patientonsetageunit": "801", "patientsex": "2", "reaction": [ { "reactionmeddraversionpt": "26.0", "reactionmeddrapt": "Blood urine present", "reactionoutcome": "3" }, { "reactionmeddraversionpt": "26.0", "reactionmeddrapt": "Conjunctivitis", "reactionoutcome": "3" }, { "reactionmeddraversionpt": "26.0", "reactionmeddrapt": "Constipation", "reactionoutcome": "3" }, { "reactionmeddraversionpt": "26.0", "reactionmeddrapt": "Urinary retention", "reactionoutcome": "3" }, { "reactionmeddraversionpt": "26.0", "reactionmeddrapt": "Neurogenic bladder", "reactionoutcome": "3" }, { "reactionmeddraversionpt": "26.0", "reactionmeddrapt": "Urinary tract infection", "reactionoutcome": "3" }, { "reactionmeddraversionpt": "26.0", "reactionmeddrapt": "Vertigo", "reactionoutcome": "3" }, { "reactionmeddraversionpt": "26.0", "reactionmeddrapt": "Fatigue", "reactionoutcome": "3" } ], "drug": [ { "drugcharacterization": "1", "medicinalproduct": "TYSABRI", "drugauthorizationnumb": "125104", "drugdosageform": "Concentrate for solution for infusion", "drugadministrationroute": "050", "drugindication": "Product used for unknown indication", "actiondrug": "5", "drugrecurreadministration": "3", "drugadditional": "3", "activesubstance": { "activesubstancename": "NATALIZUMAB" }, "openfda": { "application_number": [ "BLA125104" ], "brand_name": [ "TYSABRI" ], "generic_name": [ "NATALIZUMAB" ], "manufacturer_name": [ "Biogen Inc." ], "product_ndc": [ "64406-008" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "NATALIZUMAB" ], "rxcui": [ "477484", "603541" ], "spl_id": [ "119c87a9-d153-4796-9525-694afdcdc1d6" ], "spl_set_id": [ "c5fdde91-1989-4dd2-9129-4f3323ea2962" ], "package_ndc": [ "64406-008-01" ], "nui": [ "N0000175775", "N0000175774" ], "pharm_class_epc": [ "Integrin Receptor Antagonist [EPC]" ], "pharm_class_moa": [ "Integrin Receptor Antagonists [MoA]" ], "unii": [ "3JB47N2Q2P" ] } }, { "drugcharacterization": "1", "medicinalproduct": "OCRELIZUMAB", "drugstructuredosagenumb": "300", "drugstructuredosageunit": "003", "drugseparatedosagenumb": "1", "drugintervaldosageunitnumb": "14", "drugintervaldosagedefinition": "804", "drugdosageform": "Unknown", "drugadministrationroute": "050", "drugindication": "Relapsing-remitting multiple sclerosis", "actiondrug": "5", "drugrecurreadministration": "3", "drugadditional": "3", "activesubstance": { "activesubstancename": "OCRELIZUMAB" }, "openfda": { "application_number": [ "BLA761053" ], "brand_name": [ "OCREVUS" ], "generic_name": [ "OCRELIZUMAB" ], "manufacturer_name": [ "Genentech, Inc." ], "product_ndc": [ "50242-150" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "OCRELIZUMAB" ], "rxcui": [ "1876380", "1876385" ], "spl_id": [ "00b80381-c728-47a0-bd9e-b1223a1c0a40" ], "spl_set_id": [ "9da42362-3bb5-4b83-b4bb-b59fd4e55f0d" ], "package_ndc": [ "50242-150-01" ], "nui": [ "N0000175078", "N0000175657", "M0001357", "M0556300" ], "pharm_class_moa": [ "CD20-directed Antibody Interactions [MoA]" ], "pharm_class_epc": [ "CD20-directed Cytolytic Antibody [EPC]" ], "pharm_class_cs": [ "Antibodies, Monoclonal [CS]", "Antibodies, Monoclonal, Humanized [CS]" ], "unii": [ "A10SJL62JY" ] } }, { "drugcharacterization": "1", "medicinalproduct": "OCRELIZUMAB", "drugstructuredosagenumb": "600", "drugstructuredosageunit": "003", "drugseparatedosagenumb": "1", "drugintervaldosageunitnumb": "6", "drugintervaldosagedefinition": "802", "drugdosageform": "Solution for infusion", "drugadministrationroute": "050", "actiondrug": "5", "drugrecurreadministration": "3", "drugadditional": "3", "activesubstance": { "activesubstancename": "OCRELIZUMAB" }, "openfda": { "application_number": [ "BLA761053" ], "brand_name": [ "OCREVUS" ], "generic_name": [ "OCRELIZUMAB" ], "manufacturer_name": [ "Genentech, Inc." ], "product_ndc": [ "50242-150" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "OCRELIZUMAB" ], "rxcui": [ "1876380", "1876385" ], "spl_id": [ "00b80381-c728-47a0-bd9e-b1223a1c0a40" ], "spl_set_id": [ "9da42362-3bb5-4b83-b4bb-b59fd4e55f0d" ], "package_ndc": [ "50242-150-01" ], "nui": [ "N0000175078", "N0000175657", "M0001357", "M0556300" ], "pharm_class_moa": [ "CD20-directed Antibody Interactions [MoA]" ], "pharm_class_epc": [ "CD20-directed Cytolytic Antibody [EPC]" ], "pharm_class_cs": [ "Antibodies, Monoclonal [CS]", "Antibodies, Monoclonal, Humanized [CS]" ], "unii": [ "A10SJL62JY" ] } }, { "drugcharacterization": "2", "medicinalproduct": "ATIVAN", "drugdosageform": "Unknown", "drugadministrationroute": "050", "drugindication": "Product used for unknown indication", "activesubstance": { "activesubstancename": "LORAZEPAM" }, "openfda": { "application_number": [ "NDA017794", "NDA018140" ], "brand_name": [ "ATIVAN" ], "generic_name": [ "LORAZEPAM" ], "manufacturer_name": [ "Bausch Health US LLC", "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0187-0063", "0187-0064", "0187-0065", "0641-6000", "0641-6003", "0641-6002", "0641-6001" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL", "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "LORAZEPAM" ], "rxcui": [ "104719", "197900", "197901", "197902", "206821", "206828", "206819", "206820", "238100", "238101", "1665188", "1665190", "1665326", "1665327" ], "spl_id": [ "93bdf2de-1222-44a4-b4d5-2280f9ce58d8", "209b0091-c890-4f69-a693-d0594c2606fe" ], "spl_set_id": [ "89057c93-8155-4040-acec-64e877bd2b4c", "5fc0e987-61c9-40c4-b0d5-fcea07c8733e" ], "package_ndc": [ "0187-0063-01", "0187-0063-50", "0187-0063-10", "0187-0064-01", "0187-0064-50", "0187-0064-10", "0187-0065-01", "0187-0065-50", "0187-0065-10", "0641-6003-01", "0641-6003-25", "0641-6002-01", "0641-6002-10", "0641-6001-01", "0641-6001-25", "0641-6000-01", "0641-6000-10" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "O26FZP769L" ] } }, { "drugcharacterization": "2", "medicinalproduct": "CYCLOBENZAPRINE", "drugdosageform": "Unknown", "drugadministrationroute": "050", "drugindication": "Product used for unknown indication", "activesubstance": { "activesubstancename": "CYCLOBENZAPRINE" }, "openfda": { "application_number": [ "ANDA090478" ], "brand_name": [ "CYCLOBENZAPRINE HYDROCHLORIDE" ], "generic_name": [ "CYCLOBENZAPRINE" ], "manufacturer_name": [ "EXELAN PHARMACEUTICALS, INC.", "Cipla USA Inc." ], "product_ndc": [ "76282-283", "69097-845", "69097-846" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CYCLOBENZAPRINE HYDROCHLORIDE" ], "rxcui": [ "828348", "828320" ], "spl_id": [ "19cb705f-c529-4ad4-8eda-3a3fd48feca7", "e41dbd69-00e7-40f4-a9e7-626965badd27" ], "spl_set_id": [ "cf81da00-7c6d-4477-bb70-b3c2abea177a", "575a31fb-04c5-4001-88a7-c33adbacc6a8" ], "package_ndc": [ "76282-283-30", "76282-283-60", "76282-283-90", "76282-283-18", "76282-283-27", "76282-283-10", "69097-845-07", "69097-845-15", "69097-846-07", "69097-846-15" ], "unii": [ "0VE05JYS2P" ] } }, { "drugcharacterization": "2", "medicinalproduct": "NABILONE", "drugdosageform": "Unknown", "drugadministrationroute": "050", "drugindication": "Product used for unknown indication", "activesubstance": { "activesubstancename": "NABILONE" }, "openfda": { "application_number": [ "NDA018677" ], "brand_name": [ "CESAMET" ], "generic_name": [ "NABILONE" ], "manufacturer_name": [ "Bausch Health US LLC" ], "product_ndc": [ "0187-1231" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "NABILONE" ], "rxcui": [ "104885", "311891" ], "spl_id": [ "c8ba6520-445a-4934-85f4-6f706cb21585" ], "spl_set_id": [ "83c7ac15-ece9-47de-b83c-d575544fa449" ], "package_ndc": [ "0187-1231-50" ], "nui": [ "N0000175782", "M0003267" ], "pharm_class_epc": [ "Cannabinoid [EPC]" ], "pharm_class_cs": [ "Cannabinoids [CS]" ], "unii": [ "2N4O9L084N" ] } }, { "drugcharacterization": "2", "medicinalproduct": "TRIMETHOPRIM", "drugdosageform": "Tablets", "drugadministrationroute": "050", "drugindication": "Product used for unknown indication", "activesubstance": { "activesubstancename": "TRIMETHOPRIM" }, "openfda": { "application_number": [ "NDA018679", "ANDA091437", "ANDA216393" ], "brand_name": [ "TRIMETHOPRIM" ], "generic_name": [ "TRIMETHOPRIM" ], "manufacturer_name": [ "Dr. Reddy's Labratories Inc.", "Novel Laboratories, Inc.", "Lupin Pharmaceuticals,Inc.", "Novitium Pharma LLC" ], "product_ndc": [ "75907-043", "40032-330", "43386-330", "70954-541" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "TRIMETHOPRIM" ], "rxcui": [ "198332" ], "spl_id": [ "3523d9e9-608e-4a43-6a70-acb8c84aff7b", "63ba2637-37db-4f1e-b488-6e53466a5028", "6a57562b-424f-40ef-9b86-fa0e66c1c344", "95a1572c-6109-4d1f-bf92-262015a7654e" ], "spl_set_id": [ "73ccebc1-7412-2424-d62c-a5180ec52d81", "b27e43b5-670b-43f6-b28b-413e54f914da", "249e938d-f181-47c4-a082-372d65462f33", "95a1572c-6109-4d1f-bf92-262015a7654e" ], "package_ndc": [ "75907-043-01", "40032-330-24", "43386-330-01", "70954-541-10" ], "nui": [ "N0000175489", "N0000000191", "N0000187062", "N0000187061" ], "pharm_class_epc": [ "Dihydrofolate Reductase Inhibitor Antibacterial [EPC]" ], "pharm_class_moa": [ "Dihydrofolate Reductase Inhibitors [MoA]", "Cytochrome P450 2C8 Inhibitors [MoA]", "Organic Cation Transporter 2 Inhibitors [MoA]" ], "unii": [ "AN164J8Y0X" ] } }, { "drugcharacterization": "2", "medicinalproduct": "ZOPICLONE", "drugdosageform": "Tablets", "drugadministrationroute": "050", "drugindication": "Product used for unknown indication", "activesubstance": { "activesubstancename": "ZOPICLONE" } } ] } } ] }